We have been exploring the potential of the neuromodulator, adenosine, to reduce excessive dopamine signaling that contributes to the development and persistence of psychostimulant abuse. Dopamine’s ...
The authors conclude that nonsynaptic release of ATP and subsequent activation of adenosine A 1 receptors contributes to suppression of thalamic activity and tremor, alone and during DBS ...
Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment ...
Oxford, UK-based Exscientia has been working with German biotech Evotec on the adenosine A2a receptor antagonist, which is being tested as a treatment for adult patients with advanced solid tumours.
a drug in the adenosine A2A receptor antagonist class. The Japanese drugmaker said (PDF) the decision wasn’t taken for clinical reasons, as trials suggested the drug had potential as a ...